Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

99Tcm-LL1: a potential new bone marrow imaging agent

M Juweid1, R M Dunn, R M Sharkey

  • 1Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07103, USA.

Nuclear Medicine Communications
|February 1, 1997
PubMed
Summary

This study shows that 99Tcm-labelled LL1 monoclonal antibody provides excellent bone marrow imaging, visualizing abnormalities better than traditional sulphur colloid. LL1 offers a promising alternative for detecting bone marrow metastases and assessing blood disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.

European journal of nuclear medicine and molecular imaging·2020
Same author

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

Human vaccines & immunotherapeutics·2017
Same author

Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.

Bioconjugate chemistry·2014

Area of Science:

  • Nuclear Medicine
  • Immunoscintigraphy
  • Oncology

Background:

  • Bone marrow imaging is crucial for diagnosing hematological disorders and detecting metastatic disease.
  • Current imaging agents like 99Tcm-sulphur colloid (SC) have limitations in visualizing specific bone marrow regions.

Purpose of the Study:

  • To evaluate the efficacy of 99Tcm-labelled LL1 monoclonal antibody (MAb) for bone marrow imaging.
  • To compare the imaging quality and diagnostic utility of LL1 with 99Tcm-sulphur colloid (SC).

Main Methods:

  • Six patients with diverse diseases underwent bone marrow imaging using low-dose (<1 mg) 99Tcm-labelled LL1 Fab' (30 mCi).
  • Three patients also had 99Tcm-sulphur colloid (SC) imaging for comparative analysis.
  • Both planar and SPECT imaging were performed using Sopha gamma cameras.

Related Experiment Videos

Main Results:

  • Excellent bone marrow images were achieved as early as 2 hours post-injection with LL1.
  • LL1 demonstrated superior bone marrow-to-liver and bone marrow-to-spleen uptake ratios compared to SC (19-fold and 6-fold higher, respectively).
  • Visualization of the thoracic spine was significantly better with LL1 than with SC.

Conclusions:

  • 99Tcm-LL1 is a feasible and effective agent for bone marrow imaging.
  • LL1 offers advantages over SC, particularly in visualizing the lower thoracic spine and detecting bone marrow abnormalities.
  • Potential applications include improved detection of solid tumor metastases and assessment of hematological disorders.